BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dibattista M, Lobasso S, Stramaglia S, Corcelli A. Assessing olfactory functions in patients with Barth syndrome. PLoS One 2017;12:e0187619. [PMID: 29099864 DOI: 10.1371/journal.pone.0187619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Zegallai HM, Abu-El-Rub E, Olayinka-Adefemi F, Cole LK, Sparagna GC, Marshall AJ, Hatch GM. Tafazzin deficiency in mouse mesenchymal stem cells potentiates their immunosuppression and impairs activated B lymphocyte immune function. bioRxiv 2021:2021. [PMID: 34729562 DOI: 10.1101/2021.09.07.459330] [Reference Citation Analysis]
2 Zegallai HM, Abu-El-Rub E, Olayinka-Adefemi F, Cole LK, Sparagna GC, Marshall AJ, Hatch GM. Tafazzin deficiency in mouse mesenchymal stem cells promote reprogramming of activated B lymphocytes toward immunosuppressive phenotypes. FASEB J 2022;36:e22443. [PMID: 35816277 DOI: 10.1096/fj.202200145R] [Reference Citation Analysis]
3 Olivar-Villanueva M, Ren M, Phoon CKL. Neurological & psychological aspects of Barth syndrome: Clinical manifestations and potential pathogenic mechanisms. Mitochondrion 2021:S1567-7249(21)00084-2. [PMID: 34197965 DOI: 10.1016/j.mito.2021.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Finsterer J. Barth syndrome: mechanisms and management. Appl Clin Genet 2019;12:95-106. [PMID: 31239752 DOI: 10.2147/TACG.S171481] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]